Великобритания - английски - myHealthbox

fair-med healthcare gmbh - raloxifene hydrochloride - film-coated tablets - 60mg - selective oestrogen receptor modulator - it is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - raloxifene hydrochloride - tablet - 60mg

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - raloxifene hydrochloride - tablet - 60mg

Австралия - английски - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - raloxifene hydrochloride -

Израел - английски - Ministry of Health

eli lilly israel ltd, israel - raloxifene hydrochloride - film coated tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -

САЩ - английски - NLM (National Library of Medicine)

a-s medication solutions - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] .  raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperpl

Канада - английски - Health Canada

apotex inc - raloxifene hydrochloride - tablet - 60mg - raloxifene hydrochloride 60mg - estrogen agonist-antagonists

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - raloxifene hydrochloride -

Великобритания - английски - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - raloxifene hydrochloride - tablet - 60mg